Last edition
News about "Clinical Trial Expansion"
Arch Biopartners Advances Phase II Trial of LSALT Peptide as New Site Begins Patient Dosing
Arch Biopartners advances LSALT peptide trial for acute kidney injury as new clinical site initiates patient dosing and global expansion plans progress.
Clinical Trial Expansion | 24/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members